Express Scripts Wants Early Discussions to Help Lower Treatment Costs
After their decision to include Abbvie's triple combination for hepatitis C on their formulary, over Gilead's more expensive regimens, Express Scripts indicated at the J. P. Morgan Healthcare Conference that they'll continue the stance of choosing treatments that are equally effective but save costs, especially in cancer.
Pharma Giants to Collaborate on Immuno-oncology Regimens
Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types.
Supreme Court Rejects New Challenge to Obamacare Law
The US Supreme Court on Monday declined to take up another broad challenge to President Barack Obama's signature healthcare law, this time from the Association of American Physicians and Surgeons and the Alliance for Natural Health USA.
Supreme Court Battle Brewing Over Medicaid Fees
Providers and patient advocates nationwide are deeply worried about a US Supreme Court case that they say could restrict their ability across the country to seek judicial relief from low Medicaid reimbursement rates.
Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS
Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.
NY Telehealth Bill Signed
New telehealth bill signed into law in New York will bring much-needed healthcare to rural and underserved communities and require Medicaid to reimburse telehealth service costs.
Will Twin Medi-Cal Cuts Affect Access?
The combination of 2 Medi-Cal primary care rate decreases could mean primary care providers who see a lot of Medi-Cal patients will have to scale back or stop seeing those beneficiaries.